Triple
negative breast cancer (TNBC) remains one of the most challenging
subtypes of breast cancer to treat and is responsible for approximately
12% of breast cancer cases in the US per year. In 2019, the protein
Tinagl1 was identified as a key factor for improved prognoses in certain
TNBC patients. While the intracellular mechanism of action has been
thoroughly studied, little is known about the role of Tinagl1 in the
tumor microenvironment. In this study, we developed a lipid nanoparticle-based
gene therapy to directly target the expression of Tinagl1 in tumor
cells for localized expression. Additionally, we sought to characterize
the changes to the tumor microenvironment induced by Tinagl1 treatment,
with the goal of informing future choices for combination therapies
including Tinagl1. We found that Tinagl1 gene therapy was able to
slow tumor growth from the first dose and that the effects held steady
for nearly a week following the final dose. No toxicity was found
with this treatment. Additionally, the use of Tinagl1 increases the
tumor vasculature by 3-fold but does not increase the tumor permeability
or risk of metastasis. However, the increase in vasculature arising
from Tinagl1 therapy reduced the expression of Hif1a significantly
(p < 0.01), which may decrease the risk of drug
resistance.